-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »SEARCH RESULT
Total Matching Records found : 293
Drug makers suffer an overdose of control-Bhupesh Bhandari
-The Business Standard The new price caps for 191 essential drugs are likely to introduce serious distortions in the market for these medicines The National Pharmaceutical Pricing Authority, or NPPA, has announced new price caps for 191 essential drugs that are 10 to 50 per cent lower than the current prices. Drug makers have 45 days to recall the earlier batches and send out new ones with the lower price tags. This...
More »A flood of telegrams for PM urging an 'end to corruption' -Akshaya Mukul
-The Times of India NEW DELHI: It will be an unusual Monday morning in Prime Minister Manmohan Singh's household. Among the bagful of mail he gets daily will be several telegrams urging him to 'end corruption, give us freedom'. As the 160-year-old telegram service wound down on Sunday, one young man's idea of sending a telegram to the PM on corruption caught the fancy of others in the serpentine queue at the...
More »Kerala tackles prejudice and prices -C Maya
-The Hindu The State population stands at a little over three crore, but average consumption of drugs is three times the national average In Kerala, where people have a marked preference for branded drugs, where the most expensive brand is considered the best, and only those brands pushed by doctors sell, the new Drug (Prices Control) Order, which is expected to cut prices by 20-25 per cent, may not have much of...
More »Another bitter pill for patients-Sakthivel Selvaraj
-The Hindu The current market prices are essentially over and above the actual cost of production - a difference that could run from 100 per cent to 5,600 per cent, depending upon various therapeutic categories In a liberalised market economy, do we need price controls on drugs? Policymakers and the pharmaceutical industry do not think so. They believe that price controls are an inefficient tool that distorts resource allocation, squeezes revenue, reduces...
More »
